Circle CVI joins EXIT-CVD research consortium to advance imaging-informed, personalized cardiovascular care across Europe

• Five-yea esea ch p oject u ites 42 public a d p ivate pa t e s ac oss 17 cou t ies to co duct 22 cli ical studies i volvi g 14,000+ patie ts; fi st patie ts will be e olled this mo th
• P oject aims to help ca diac patie ts avoid dete io atio th ough ea ly, pe so alized i te ve tio s delive ed ac oss the ca diac ca e jou ey
• I te ve tio s will be co-c eated with patie ts a d desig ed to systematically add ess socioeco omic, sex- a d ge de – elated a d digital access gaps
• With a total budget of EUR 27.6 millio , the p oject is co-fu ded by the Eu opea U io I ovative Health I itiative (IHI) a d i dust y pa t e s
• Ci cle CVI b i gs expe tise i AI-e abled ca diovascula MR a d CT image a alysis, suppo ti g the co so tium’s focus o ea lie diag osis, pe so alized isk assessme t a d imagi g-guided ca e.

CALGARY, Albe ta, Oct. 20, 2026 (GLOBE NEWSWIRE) — Ci cle Ca diovascula Imagi g (Ci cle CVI), a p ovide of AI-e abled ca diovascula imagi g softwa e, today a ou ced its pa ticipatio i EXIT-CVD, a five-yea esea ch p oject b i gi g togethe 42 public a d p ivate pa t e s ac oss 17 cou t ies. Co-fu ded by the Eu opea U io ’s I ovative Health I itiative (IHI) a d i dust y pa t e s, the co so tium is led by U ive sity Medical Ce te G o i ge (UMCG) a d Philips a d aims to t a sfo m how ca diovascula disease is detected, mo ito ed a d t eated. The p oject will co duct 22 cli ical studies i volvi g mo e tha 14,000 patie ts, i vestigati g oppo tu ities to p eve t disease befo e it develops, eve se disease p og essio o halt dete io atio i adva ced disease. Patie t e ollme t fo the fi st studies is scheduled to begi i Octobe 2026.

Ca diovascula health is fu dame tal to ove all health a d well-bei g, yet mo e tha 60 millio people i the Eu opea U io a e livi g with ca diovascula disease. Fo ma y, the co ditio sig ifica tly educes quality of life a d well-bei g. Without ea ly detectio , timely diag osis a d app op iate t eatme t, ca diovascula disease ca p og ess sile tly f om ea ly isk facto s to established disease a d ultimately, ca diac eve ts that may lead to p ematu e death.

“Ou visio is a futu e whe e hea t disease is o lo ge a i eve sible pathway,” said P ofesso Pim va de Ha st, P oject Coo di ato of EXIT-CVD a d Head of Ca diology at the U ive sity Medical Ce te G o i ge . “By u de sta di g both the biological a d social d ive s of ca diovascula disease, a d deployi g i teg ated i ovatio s ac oss diag ostics, mo ito i g, a d ca e, we ca empowe patie ts a d cli icia s to exit the disease co ti uum befo e it’s too late.”

“Fo mo e tha 30 yea s, we have viewed ca diovascula disease as a co ti uous jou ey, f om isk facto s such as hype te sio , to athe oscle osis, a fi st ca diac eve t a d ultimately, fo ma y patie ts, hea t failu e,” said Robi Nijveldt, Chief of Ca diology at UMC Ut echt. “Yet most of us imp ove ca e withi ou ow specialty a d a ely have a complete view of the patie t’s expe ie ce. EXIT-CVD is a ambitious effo t to build that holistic view togethe , helpi g t a sfo m ca diac ca e fo millio s of patie ts ac oss Eu ope.”

The EXIT-CVD cli ical studies will focus o the th ee key exit poi ts alo g the ca diac ca e jou ey: ea ly detectio th ough digital mo ito i g (ea ly exit), pe so alized isk assessme t a d ta geted i te ve tio s (mid exit), a d adva ced the apies to suppo t ecove y i late -stage disease (late exit). By combi i g diag ostics, digital tools a d adva ced the apeutic app oaches, EXIT-CVD aims to delive actio able, evide ce-based st ategies that ca be impleme ted ac oss dive se healthca e systems i Eu ope.

I ovatio that eaches eve yo eNew diag ostics a d digital tools ofte each well- esou ced populatio s fi st, wide i g gaps i access a d outcomes. The p oject will the efo e embed impleme tatio scie ce a d equity-by-desig p i ciples to e su e that the solutio s a e scalable, sustai able, a d accessible to all eleva t populatio s, i cludi g those histo ically u de se ved. A digitally e abled, FAIR-complia t data platfo m alig ed with the Eu opea Health Data Space (EHDS) will suppo t the i teg atio , evaluatio , a d eal-wo ld scalability of the p oject’s i ovatio s.

“Adva ced ca diovascula imagi g ca help cli icia s u de sta d ot o ly what disease looks like today, but how it may p og ess a d whe e i te ve tio could make a diffe e ce,” said E ka Akyuz, CEO at Ci cle Ca diovascula Imagi g. “EXIT-CVD b i gs togethe the cli ical, tech ology a d patie t pe spectives eeded to explo e those oppo tu ities ac oss the ca e jou ey. We a e p oud to joi this collabo atio a d b i g ou expe tise i AI-e abled image a alysis to its ambitio of ea lie , mo e pe so alized ca diovascula ca e.”

Ci cle CVI b i gs expe tise i AI-e abled ca diovascula image a alysis th ough its cvi42 platfo m, which combi es ca diac MR a d CT a alysis, co o a y plaque qua tificatio , a d tools fo st uctu al hea t a d elect ophysiology p ocedu e pla i g withi a u ified e vi o me t. Its capabilities i clude assessme t of ca diac fu ctio , blood flow, myoca dial tissue cha acte istics a d co o a y a te y disease, helpi g cli icia s t a slate complex imagi g data i to qua titative fi di gs. This expe tise alig s EXIT-CVD’s emphasis o imagi g-guided disease st atificatio a d pe so alized cli ical decisio -maki g.

Cli ical studiesThe EXIT-CVD esea ch co so tium will co duct a total of 22 cli ical studies i volvi g mo e tha 14,000 patie ts ac oss Eu ope, i cludi g:

• Came a-Based I -Hospital Mo ito i g (CARDIO-CAM study): Deployme t a d evaluatio of a u obt usive, video-based patie t mo ito i g system that co ti uously captu es ca dio espi ato y sig als a d eleva t cli ical co text.
• Spect al CT fo Ea ly Detectio , Risk St atificatio a d Pe so alized Patie t Ca e Pathways (LEADER-PAD study): Developme t a d validatio of ew app oaches fo the ea ly detectio of ca diovascula disease i asymptomatic a d low isk symptomatic patie ts usi g spect al CT.
• Nu se/HCP-Led Remote Hea t Failu e Mo ito i g (REMODEL-HF study): Multi atio al a domized study evaluati g the Hea t Failu e Ma ageme t System (HFMS), a o -i vasive emote mo ito i g tech ology, i patie ts ece tly hospitalized fo hea t failu e, with the objective of imp ovi g outcomes a d optimizi g guideli e-di ected medical the apy.
• Imagi g-Guided PCI Ra domized T ial (GUIDANCE-PCCT study): Evaluatio of cli ical a d p ocedu al outcomes of PCI guided by photo cou ti g CT ve sus sta da d a giog aphy-guided PCI.
• Adva ced Imagi g i I filt ative Ca diomyopathies (NOTIFY-2 study): Validatio of AI-d ive image a d ECG a alysis algo ithms to imp ove ea ly diag osis of Left Ve t icula Hype t ophy (LVH) a d u de lyi g disease isk st atificatio .

Co so tium pa t e sThe IHI EXIT-CVD public-p ivate pa t e ship comp ises 42 pa t e o ga izatio s f om 17 cou t ies:

• Cli ical a d academic pa t e s: Hospital de la Sa ta C eu i Sa t Pau (Spai ), Politec ico di Mila o (Italy), U ive sity of Pavia (Italy), Ce t o Ca diologico Mo zi o (Italy), EOC (Switze la d), KU Leuve (Belgium), NIKARD (Pola d), UMC Ut echt (Nethe la ds), UMC G o i ge (Nethe la ds), Tech ical U ive sity Ei dhove (Nethe la ds), U ive sitätskli ikum Köl (Ge ma y), Ki g’s College Lo do (UK), Lo do School of Eco omics a d Political Scie ce (UK), a d Va si ais-Suome Hyvi voi tialue (Fi la d).
• I dust y pa t e s: Philips, Ci cle CVI, GE Healthca e, Sieme s Healthi ee s, Hea tBeam, Medt o ic, Huawei, XVIVO Pe fusio , Ast aZe eca, Ca diomed, Megi Health, Viat is, Co dys, Nova tis, Co botics, ZOLL, Sa ofi, Repai o , Joh so & Joh so MedTech Hea t Recove y, O se tia, a d CogStack
• Healthca e co sulta cy: B idg Ou a d IQVIA Solutio s
• Patie t o ga izatio : Stichti g V ouwe Ha t
• Medical associatio : Eu opea Society of Ca diology (ESC)

Mo e i fo matio ca be viewed o the EXIT-CVD website.

This p oject is suppo ted by the I ovative Health I itiative Joi t U de taki g (IHI JU) u de g a t ag eeme t No 101253160. The JU eceives suppo t f om the Eu opea U io ‘s Ho izo Eu ope esea ch a d i ovatio p og am a d COCIR, EFPIA, Eu opa Bío, MedTech Eu ope, a d Vacci es Eu ope. Fu ded by the Eu opea U io , the p ivate membe s, a d those co t ibuti g pa t e s of the IHI JU. Views a d opi io s exp essed a e those of the autho (s) o ly a d do ot ecessa ily eflect those of the afo eme tio ed pa ties. Neithe of the afo eme tio ed pa ties ca be held espo sible fo them.

Fo fu the i fo matio , please co tact:

ma keti g@ci clecvi.com

Ci cle Ca diovascula Imagi g (Ci cle CVI) develops AI-e abled softwa e fo ca diovascula image a alysis, visualizatio a d epo ti g. Its flagship platfo m, cvi42, b i gs togethe ca diac MR, ca diac CT, vascula CT, st uctu al hea t pla i g a d elect ophysiology pla i g tools i a u ified, ve do – eut al e vi o me t. Desig ed fo cli ical a d esea ch wo kflows, Ci cle’s solutio s combi e automated a alysis, qua titative assessme t a d i teg ated epo ti g to suppo t efficie t, ep oducible ca diovascula imagi g. Fo mo e i fo matio , visit www.ci clecvi.com.